Swine Trials

Average Daily Gain (ADG) Day 0 - 28 (Starter) Kg/Head/Day

A trial conducted in 2014 by the National Institute of Animal Sciences for Vietnam demonstrated favorable results for OxC-beta, in both starter piglet and grower populations. There were 500 weaned piglets (aged 28 days at Day 0) enrolled in the trial for a treatment period of 140 days. The piglets were separated into 5 treatment groups:

Group 1: Negative control
Group 2: Positive control: Standard antibiotic growth promoter (*)
Group 3: 2ppm OxC-beta
Group 4: 4ppm OxC-beta
Group 5: 8ppm OxC-beta

 

Miode_of_action

The dataset from this study is currently incomplete, with only the results from day 0-84 being fully available. A full 140-day report is expected in early 2015, which will include histological and immune marker geneexpression data as well as the impacts on carcass quality. Initial results are promising, however, with OxC-beta outperforming both the negative and positive control (medicated) groups across a number of parameters. This OxC-beta outperformance occurred for all doses of OxC-beta that were tested.

  1. Average daily gains in the OxC-beta treated groups improved 5-23% relative to the control groups. The most significant improvement was seen in the starter groups.
  2. Feed conversion ratio in the OxC-beta treated groups improved by 5-11% relative to unsupplemented control groups.
  3. Significant improvement in diarrhea scores were also observed across the dose intervals tested in the OxC-beta treated groups.

 

Initial results from this clearly study demonstrate that OxC-beta has a beneficial effect in maintaining and enhancing the growth and health of pigs across their full post-wean growth cycle. The results also show that OxC-beta outperforms antibiotics across a number of parameters therefore offering producers a viable and efficacious alternative to traditional antibiotics.

Body_weight
Conversion_Ratio
Daily_Gain
PRRS_Virus

Wean_Diarrhea

 

*150 ppm Chlortetracycline, 100ppm Colistin sulphate Average daily gains in the OxC